ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1114

Nintedanib in Autoimmune Disease-related Interstitial Lung Disease: Real-life Effectiveness, Safety and Tolerance in a Spanish Multicenter Study

paula pérez garcía1, Miriam Retuerto Guerrero2, yanira chuquimia mendoza3, Jesús Loarce4, Belén Atienza-Mateo5, Carolina Merino6, marina pavia pascual7, cristiana sieiro santos8, Clara Moriano9 and elvira Diez álvarez10, 1Complejo Asistencial Universitario de León, león, Spain, 2Complejo Asistencial Universitario de León, Leon, Spain, 3Complejo asistencial univeritario de león, león, Spain, 4Ramón y Cajal University Hospital, Madrid, Madrid, Spain, 5Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Cantabria, Spain, 6Hospital Universitario Puerta de Hierro Majadahonda., Majadahonda (Madrid), Spain, 7Hospital General Universitario Gregorio Marañon, madrid, Spain, 8Rheumatology Department, Complejo Asistencial Universitario de León, León, Spain, Leon, Spain, 9Hospital León, LEON, Spain, 10Complejo Asistencial Universitario de Leon, Leon

Meeting: ACR Convergence 2024

Keywords: autoimmune diseases, Biostatistics, pulmonary, registry

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 17, 2024

Title: Miscellaneous Rheumatic & Inflammatory Diseases Poster II

Session Type: Poster Session B

Session Time: 10:30AM-12:30PM

Background/Purpose: Interstitial lung disease (ILD) is a severe complication of autoimmune diseases (AD). In recent years, new strategies for the treatment of progressive pulmonary fibrosis (PPF) have been developed. Nintedanib (NINTE) has been the first antifibrotic drug approved for the treatment of progressive fibrosing autoimmune diseaserelated ILDs (INBUILD and SENSCIS trials).
The goals of our research were to evaluate the efficacy, safety and tolerance of NINTE in real-life AD-ILD patients in Spain.

Methods: A multicenter retrospective observational study was performed. We obtained data from medical records of 67 patients with AD-ILD treated with nintedanib 150 mg twice daily. Epidemiological and clinical data, highresolution computed tomography (HRCT) findings, pulmonary function tests (PFT), antibody status, and concomitant immunosuppressive drugs were also recorded. Statistical analyses were performed using Student’s test or Mann-Whitney’s T test for continuous variables and Chi2 test or Fisher’s exact test for categorical variables. A p value < 0.05 was considered significant.

Results: 67 patients from six centers were included. 58% were female, median age at NINTE onset was 63.8 (56.8-72.6) years. The median disease duration was 4.1 (0.9-12.2) years for AD and 3.6 (1.6-5.9) years for ILD. Fourteen (23%) patients were diagnosed of rheumatic disease after ILD diagnosis. Clinical, immunological, radiological and treatment data are summarized in Table 1. NSIP pattern was associated with ANA (p=0.004) and cotreatment with mycophenolate mofetil (p=0.003) and rituximab (p=0.003). UIP pattern was associated with tobacco (p=0.046) and the presence of radiographic emphysema (p=0.032), RA patients (p=0.001), RF (p=0.001) and ACCP antibodies (p< 0.001). At one-year of follow-up, worsening of chest HRCT images was found in 31% of patients. Radiographic progression was associated with UIP pattern (OR 8.5 CI 1.5-46.8, p=0.014), RA diagnosis (OR 8, CI 51.7-38.4, p=0.017,) and ACCP antibodies (OR 11.2 CI 2.1-58.9, p=0.004). At baseline, predicted FVC% and DLCO% were 46 (34-57) and 71 (52.5-84.8); at six-month of follow-up were 46 (33-56) and 69 (57-82.5); and at one-year of follow-up were 44 (39.5-58) and 69 (54.8-84) respectively. No significant differences were found in PFT evolution between groups of HRCT patterns, rheumatic disease, autoantibodies and concomitant treatment. The median duration of NINTE treatment was 13.2 (8-26.9) months. Adverse events led to NINTE withdrawal in 13 patients, and 16 subjects required a dose reduction to 150 mg daily. During follow-up, 16
patients were admitted for ILD exacerbation, and 11 patients died. Ro52-positive patients and those treated with leflunomide were more likely to be admitted for pulmonary exacerbation. Factor associated with mortality are described in Table 2.

Conclusion: In our cohort, despite the great heterogeneity, NINTE appears to prevent interstitial lung progression in all subgroups regardless of the type of AD, concomitant treatment or time since diagnosis of pulmonary involvement. UIP pattern, ACCP antibodies, cardiological comorbidity, ILD exacerbation and DLCO% value at 6 months were linked to mortality.

Supporting image 1

Supporting image 2


Disclosures: p. pérez garcía: None; M. Retuerto Guerrero: None; y. chuquimia mendoza: None; J. Loarce: None; B. Atienza-Mateo: None; C. Merino: None; m. pavia pascual: None; c. sieiro santos: None; C. Moriano: None; e. Diez álvarez: None.

To cite this abstract in AMA style:

pérez garcía p, Retuerto Guerrero M, chuquimia mendoza y, Loarce J, Atienza-Mateo B, Merino C, pavia pascual m, sieiro santos c, Moriano C, Diez álvarez e. Nintedanib in Autoimmune Disease-related Interstitial Lung Disease: Real-life Effectiveness, Safety and Tolerance in a Spanish Multicenter Study [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/nintedanib-in-autoimmune-disease-related-interstitial-lung-disease-real-life-effectiveness-safety-and-tolerance-in-a-spanish-multicenter-study/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/nintedanib-in-autoimmune-disease-related-interstitial-lung-disease-real-life-effectiveness-safety-and-tolerance-in-a-spanish-multicenter-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology